市場調查報告書
商品編碼
1471071
血漿分餾市場:按產品、應用和最終用戶分類 - 2024-2030 年全球預測Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
血漿分餾市場規模預計2023年為355.2億美元,2024年達389.5億美元,預計2030年將達到712.7億美元,複合年成長率為10.45%。
血漿分餾是指收集、分離和精製人類血漿中存在的各種必需成分,主要包括白蛋白、免疫球蛋白、凝血因子和其他蛋白質。這些成分在醫學上有許多用途,包括血友病治療、免疫疾病治療、創傷治療支持、神經治療和其他罕見疾病。由於原始血漿是多種救生治療的關鍵組成部分,對原始血漿的需求正在穩步成長。這種激增是由於人口老化和免疫疾病盛行率上升所致,這些疾病更容易患上需要血液治療的慢性疾病。此外,患者對血液相關疾病的認知不斷提高也大大促進了該市場的擴張。然而,政府對血漿分餾和替代重組療法的嚴格監管可能會阻礙市場需求。生產技術的新進步將進一步增加該領域參與者的商機。此外,預計各相關人員之間的策略聯盟將推動產業內的創新研究工作,提供新穎的解決方案並在預測期內創造利潤豐厚的市場機會。
主要市場統計 | |
---|---|
基準年[2023] | 355.2億美元 |
預測年份 [2024] | 389.5億美元 |
預測年份 [2030] | 712.7億美元 |
複合年成長率(%) | 10.45% |
在產品免疫球蛋白精製中增加血漿分餾的使用
白蛋白是一種主要的血漿蛋白,對於調節血液容量和運輸多種物質(包括荷爾蒙、藥物和營養物質)非常重要。免疫球蛋白製劑主要用於治療低血容、低白蛋白血症和嚴重燒傷。凝血因子濃縮物對於治療A型血友病等出血性疾病至關重要,並且可以促進血管性血友病的癒合。免疫球蛋白是透過中和細菌和病毒等病原體在人體免疫反應中發揮重要作用的抗體,通常用於原發性免疫力缺乏疾病、發炎疾病、自體免疫疾病和某些類型的癌症的治療。蛋白酶抑制劑對於治療遺傳性血管性水腫 (HAE) 至關重要。遺傳性血管性水腫是一種週期性遺傳性疾病,其特徵是身體不同部位反覆發作嚴重腫脹。這些抑制劑可阻斷蛋白酶的作用,從而在遺傳性血管性水腫 (HAE) 發作期間引起發炎和血管滲透性。
應用 擴大在血液疾病治療的應用
在重症加護中,血漿分餾產品對於治療敗血症、燒傷和創傷等危及生命的疾病至關重要。血漿分餾在血液腫瘤學中具有重要應用,可支持血液相關癌症的治療和化療。血液學涉及血友病和馮維勒布蘭德病 (VWD) 等血液疾病的預防、診斷和治療。含有 IVIG 的血漿分餾產品擴大用於治療神經系統疾病,如Guillain-Barré二氏症候群、慢性脫髓鞘多發性神經炎(CIDP) 和多發性硬化症。在呼吸系統醫學中,血漿分餾可用於治療 α-1 抗胰蛋白酶缺乏症 (AATD) 和急性呼吸窘迫症候群(ARDS) 等呼吸系統疾病。血漿分餾用於風濕病學,主要透過使用 IVIG 來治療自體免疫和發炎疾病。
最終用戶:血漿分餾廣泛用於臨床研究實驗室,以確保血漿衍生產品的安全性和有效性。
學術和研究機構從事基礎研究,以提高我們對血漿蛋白及其治療潛力的了解。此細分市場的主要需求包括用於蛋白質表徵研究的高純度血漿分餾、用於發現的先進分餾技術以及獲得可靠的原料來源。臨床研究實驗室對於測試和檢驗製程和產品至關重要。我們進行測試以確保血漿衍生產品的安全性和有效性,評估患者影響並收集資料以支持監管核准。這些實驗室參與產品開發的臨床前和臨床階段。
區域洞察
由於其完善的醫療基礎設施、免疫不全症的高盛行率以及不斷成長的老年人口,美洲在血漿分餾市場中佔有重要地位。在歐洲,歐盟國家擁有強而有力的法規結構來管理血漿分餾產業。歐洲藥品管理局 (EMA) 負責監管血液產品的製造方法並監督品質標準,是該地區市場需求的主要推動者。由於收入的增加和醫療保健服務的擴大,中東和非洲地區提供了利潤豐厚的機會。在亞太地區,快速的都市化和經濟發展正在推動醫療基礎設施投資,市場格局正在向新興市場演變。此外,亞太地區各國政府也越來越關注血液安全法規,為市場進入者創造了機會。
FPNV定位矩陣
FPNV定位矩陣對於評估血漿分餾市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對血漿分餾市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.血漿分餾市場的市場規模與預測是多少?
2.血漿分餾市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?
3.血漿分餾市場的技術趨勢和法規結構是什麼?
4.血漿分餾市場主要廠商的市場佔有率為何?
5.進入血漿分餾市場適合的形式和策略手段是什麼?
[197 Pages Report] The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.
Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market's expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 35.52 billion |
Estimated Year [2024] | USD 38.95 billion |
Forecast Year [2030] | USD 71.27 billion |
CAGR (%) | 10.45% |
Product: Rising use of plasma fractionation for immunoglobulins purification
Albumin is a major plasma protein critical in regulating blood volume and transporting various substances, including hormones, drugs, and nutrients. It primarily treats hypovolemia (low blood volume), hypoalbuminemia (low albumin levels), and severe burns. Coagulation factor concentrates are essential for treating bleeding disorders such as hemophilia A & B and von Willebrand disease and replace missing or deficient clotting factors, preventing excessive bleeding and promoting proper wound healing. Immunoglobulins are antibodies that play a crucial role in the body's immune response by neutralizing pathogens such as bacteria and viruses and are used to treat primary immunodeficiency diseases, inflammatory and autoimmune disorders, and certain types of cancer. Protease inhibitors are essential for managing hereditary angioedema (HAE), a periodic genetic condition characterized by recurrent episodes of severe swelling in various body parts. These inhibitors block the action of proteases responsible for inflammation and vascular permeability during hereditary angioedema (HAE) attacks.
Application: Proliferating use to treat hematological disorders
In the critical care setting, plasma fractionation products are vital for treating life-threatening conditions such as sepsis, burns, and trauma. Plasma fractionation has significant applications in hemato-oncology for managing blood-related cancers and supporting chemotherapy treatments. Hematology involves the prevention, diagnosis, and treatment of blood diseases such as hemophilia or von Willebrand disease (VWD). Plasma fractionation products including IVIG are increasingly used in treating neurological conditions, including Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multiple sclerosis. In pulmonology, plasma fractionation helps in managing respiratory diseases such as alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS). Plasma fractionation is utilized in rheumatology primarily through the use of IVIG to manage autoimmune and inflammatory disorders.
End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products
Academic & research institutes are engaged in basic research to advance the understanding of plasma proteins and their therapeutic potential. The key needs for this segment include high-purity plasma fractions for protein characterization studies, advanced fractionation techniques that can lead to discoveries, and access to reliable sources of raw material. Clinical research laboratories are essential for testing and validating plasma fractionation processes and products. They conduct trials to ensure the safety and efficacy of plasma-derived products, assess their impact on patients, and gather data to support regulatory approval. These laboratories are involved in both pre-clinical and clinical stages of product development.
Regional Insights
The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region's market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Plasma Fractionation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Plasma Fractionation Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Fractionation Market?
3. What are the technology trends and regulatory frameworks in the Plasma Fractionation Market?
4. What is the market share of the leading vendors in the Plasma Fractionation Market?
5. Which modes and strategic moves are suitable for entering the Plasma Fractionation Market?